
    
      In this phase IV clinical trial the Month 3 visit assessments will be used to assess the
      efficacy (quality of vision and other parameters) and safety of IKERVIS® in DED patients with
      severe keratitis.

      To assess the effect on the quality of vision of IKERVIS® (1mg/ml ciclosporin) eye drops
      administered once daily in adult dry eye disease (DED) patients with severe keratitis over 3
      months of treatment.

      To assess the safety of DED patients with severe keratitis treated with IKERVIS® (1mg/mL
      ciclosporin) for 3 months.
    
  